

PATENT APPLICATION
ATTORNEY DÖÖKET NO: 27866/34810

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applica	ation of:) I hereby certify that this paper is being deposited
	ti t) with the United States Postal Service as First
Patrick Gray et al.) Class mail, postage prepaid, in an envelope
) addressed to: Commissioner for Patents,
Serial No: 09/509,165) Washington, D.C. 20231 on February 25, 2002.
	•	RECEIVED
Filed: June 12, 2000)
		MAR 12 2002
For:	Macrophage Derived Chemokine) THIN I Z LUUL
	(MDC), MDC Analogs, MDC	
	Inhibitor Substances, and Uses	TECH CENTER 1600/2900
	Thereof	Sharan M. Sintish
		Sharon M. Sintich
Art Unit: 1648		Registration No. 48,484
	•	Agent for Applicants
Examiner: B. Li)

AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents Washington, DC 20231

Sir:

This is in response to a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed January 23, 2002 (copy enclosed herewith). The Patent Office indicated that the above-identified application failed to comply with one or more of the requirements of 37 C.F.R. §§ 1.821-1.825, pertaining to Sequence Listings. The applicants request entry of the following amendments to correct the Sequence Listing.